Jim Simons Prothena Corp Public LTD CO Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Renaissance Technologies LLC holds 182,800 shares of PRTA stock, worth $2.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

182,800

Previous 329,500 44.52%

Holding current value

$2.63 Million

Previous $6.8 Million 55.03%

% of portfolio

0.0%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$16.73 - $24.79 $2.45 Million - $3.64 Million	-146,700 Reduced 44.52%	182,800 $3.06 Million
Q2 2024 Aug 09, 2024	SELL	$19.54 - $26.15 $1.18 Million - $1.57 Million	-60,200 Reduced 15.45%	329,500 $6.8 Million
Q1 2024 May 13, 2024	BUY	$24.75 - $40.66 $1.33 Million - $2.19 Million	53,900 Added 16.05%	389,700 $9.65 Million
Q4 2023 Feb 13, 2024	BUY	$32.31 - $52.32 $2.43 Million - $3.93 Million	75,200 Added 28.86%	335,800 $12.2 Million
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $2.99 Million - $4.46 Million	-63,200 Reduced 19.52%	260,600 $12.6 Million
Q2 2023 Aug 11, 2023	SELL	$48.26 - $78.59 $4.03 Million - $6.56 Million	-83,500 Reduced 20.5%	323,800 $22.1 Million
Q1 2023 May 12, 2023	SELL	$46.97 - $58.27 $3.18 Million - $3.94 Million	-67,600 Reduced 14.23%	407,300 $19.7 Million
Q4 2022 Feb 13, 2023	SELL	$52.05 - $65.0 $8.43 Million - $10.5 Million	-162,000 Reduced 25.44%	474,900 $28.6 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $1.24 Million - $2.98 Million	-49,100 Reduced 7.16%	636,900 $38.6 Million
Q2 2022 Aug 12, 2022	BUY	$22.73 - $39.98 $6.63 Million - $11.7 Million	291,800 Added 74.02%	686,000 $18.6 Million
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $3.86 Million - $6.27 Million	127,400 Added 47.75%	394,200 $14.4 Million
Q4 2021 Feb 11, 2022	BUY	$42.11 - $73.26 $404,256 - $703,296	9,600 Added 3.73%	266,800 $13.2 Million
Q3 2021 Nov 12, 2021	BUY	$48.2 - $78.89 $910,980 - $1.49 Million	18,900 Added 7.93%	257,200 $18.3 Million
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $1.1 Million - $2.92 Million	-50,700 Reduced 17.54%	238,300 $12.3 Million
Q1 2021 May 13, 2021	SELL	$11.0 - $28.24 $275,000 - $706,000	-25,000 Reduced 7.96%	289,000 $7.26 Million
Q4 2020 Feb 10, 2021	BUY	$10.12 - $13.94 $493,855 - $680,272	48,800 Added 18.4%	314,000 $3.77 Million
Q3 2020 Nov 13, 2020	SELL	$9.93 - $13.47 $1.22 Million - $1.65 Million	-122,762 Reduced 31.64%	265,200 $2.65 Million
Q2 2020 Aug 13, 2020	BUY	$9.56 - $12.51 $2.9 Million - $3.79 Million	303,062 Added 356.96%	387,962 $4.06 Million
Q1 2020 May 14, 2020	BUY	$7.54 - $15.77 $119,132 - $249,166	15,800 Added 22.87%	84,900 $908,000
Q4 2019 Feb 13, 2020	BUY	$7.48 - $17.01 $180,268 - $409,941	24,100 Added 53.56%	69,100 $1.09 Million
Q3 2019 Nov 13, 2019	BUY	$6.89 - $10.45 $310,050 - $470,249	45,000 New	45,000 $353,000
Q2 2019 Aug 12, 2019	SELL	$8.85 - $12.49 $113,280 - $159,872	-12,800 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$10.32 - $14.49 $132,096 - $185,472	12,800 New	12,800 $155,000

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $676M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account